Published in Ann Intern Med on July 06, 2004
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) | NCT00000542
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02
Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use. Arch Intern Med (2010) 1.64
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation (2011) 1.52
Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look. Hypertension (2007) 1.22
The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer (2008) 1.12
Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vasc Health Risk Manag (2009) 0.88
ALLHAT: what has it taught us so far? CMAJ (2004) 0.88
Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project. Clin Trials (2009) 0.86
Publishing commentary by authors with potential conflicts of interest: when, why, and how. Ann Intern Med (2004) 0.84
Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome? J Clin Hypertens (Greenwich) (2009) 0.84
Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]). Am J Cardiol (2015) 0.75
Clinical trials of antihypertensives: Nature of control and design. Indian J Pharmacol (2011) 0.75
Angiotensin-converting enzyme inhibitors and diuretics: optimal combination therapy. Ann Intern Med (2004) 0.75
Aliskiren in hypertension: evidence for its potential therapeutic value. Core Evid (2005) 0.75
ALLHAT, or the soft science of the secondary end point. Ann Intern Med (2003) 4.46
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med (2010) 8.48
Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA (2002) 7.93
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol (2009) 7.86
The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA (2003) 7.42
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ (2011) 6.19
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA (2007) 5.02
APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med (2013) 5.00
Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA (2004) 4.71
Trends in blood pressure among children and adolescents. JAMA (2004) 4.03
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA (2005) 3.89
Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation (2003) 3.76
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med (2008) 3.71
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation (2006) 3.69
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care (2008) 3.65
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ (2009) 3.65
Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care (2007) 3.62
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ (2008) 3.56
Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke (2004) 3.26
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA (2004) 3.20
Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med (2002) 3.17
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2008) 3.15
Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 3.10
Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke (2002) 3.05
Individual blood pressure responses to changes in salt intake: results from the DASH-Sodium trial. Hypertension (2003) 2.87
Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. Circulation (2008) 2.85
Joint effects of sodium and potassium intake on subsequent cardiovascular disease: the Trials of Hypertension Prevention follow-up study. Arch Intern Med (2009) 2.81
Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med (2014) 2.81
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med (2006) 2.81
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2008) 2.67
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Clin Hypertens (Greenwich) (2013) 2.64
Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology (2013) 2.61
Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis (2012) 2.51
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation (2008) 2.51
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Rosiglitazone and cardiovascular risk. N Engl J Med (2007) 2.41
Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med (2007) 2.41
Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med (2003) 2.40
COX-2 inhibitors--lessons in drug safety. N Engl J Med (2005) 2.39
Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis (2009) 2.39
Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Prev Med (2010) 2.36
The rationale and design of the AASK cohort study. J Am Soc Nephrol (2003) 2.34
Recent trials in hypertension: compelling science or commercial speech? JAMA (2006) 2.30
A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes (2011) 2.29
The safety risks of innovation: the FDA's Expedited Drug Development Pathway. JAMA (2012) 2.28
Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol (2003) 2.21
From knowledge to practice in chronic cardiovascular disease: a long and winding road. J Am Coll Cardiol (2004) 2.16
Differences in medical care and disease outcomes among black and white women with heart disease. Circulation (2003) 2.16
Ensuring the integrity of clinical practice guidelines: a tool for protecting patients. BMJ (2013) 2.06
The necessity for clinical reasoning in the era of evidence-based medicine. Mayo Clin Proc (2013) 2.06
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med (2005) 1.99
Lead editorial: trials - using the opportunities of electronic publishing to improve the reporting of randomised trials. Trials (2006) 1.98
Obesity research--limitations of methods, measurements, and medications. JAMA (2006) 1.97
Age as a modifiable risk factor for cardiovascular disease. Lancet (2008) 1.94
Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosis. J Am Soc Nephrol (2010) 1.92
Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002. JAMA (2004) 1.85
Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States. Hypertension (2006) 1.82
A longitudinal study of left ventricular function and structure from CKD to ESRD: the CRIC study. Clin J Am Soc Nephrol (2013) 1.72
Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst (2006) 1.70
Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis (2006) 1.68
Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis (2008) 1.68
Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial. Hypertension (2011) 1.65
Suicidal behavior and depression in smoking cessation treatments. PLoS One (2011) 1.65
Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use. Arch Intern Med (2010) 1.64
Varenicline and suicide. Risk of psychiatric side effects with varenicline. BMJ (2009) 1.63
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol (2012) 1.62
Body weight changes with beta-blocker use: results from GEMINI. Am J Med (2007) 1.60
The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med (2007) 1.60
Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. JAMA (2004) 1.60
Thoughts and acts of aggression/violence toward others reported in association with varenicline. Ann Pharmacother (2010) 1.59
Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes (2012) 1.59
Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. BMJ (2010) 1.58